NCT01012895 - Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

February 28, 2014

Conditions

Chronic Hepatitis C

Interventions

DRUG

BMS-790052

Tablets, Oral, 60 mg, once daily, 24 weeks

DRUG

BMS-650032

Tablets, Oral, 600 mg, twice daily, 24 weeks

DRUG

BMS-650032

Tablets, Oral, 200mg, twice daily, 24 weeks

DRUG

BMS-650032

Tablets, Oral, 200 mg, once daily, 24 weeks

DRUG

Pegylated-interferon alfa-2a

Syringe, Subcutaneous Injection, 180 µg, once weekly

DRUG

Ribavirin

"Tablets, Oral~For subjects weighing \< 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (\< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"

Trial Locations (18)

13285

Local Institution, Marseille

21202

Mercy Medical Center, Baltimore

22031

Metropolitan Research, Fairfax

28677

Carolinas Center For Liver Disease, Statesville

33604

Local Institution, Pessac

48109

University Of Michigan Health System, Ann Arbor

75571

Local Institution, Paris

75651

Local Institution, Paris

75679

Local Institution, Paris

76012

Texas Clinical Research Institute, Llc, Arlington

78215

Alamo Medical Research, San Antonio

80045

University Of Colorado Denver & Hospital, Aurora

92118

Southern California Liver Centers, Coronado

Local Institution, Clichy

92801

Advanced Clinical Research Institute, Anaheim

94010

Local Institution, Créteil

95128

San Jose Gastroenterology, San Jose

00927

Local Institution, San Juan